Enhancing Novel Biotherapeutic Developability Through Automated And Scalable MS Analytics

By Ada Yee, Scientific Communications

This content is brought to you by Genedata, a Danaher Operating Company.

The rise of complex biotherapeutics is placing unprecedented pressure on analytical teams to generate fast, reliable insights into molecular quality and developability. Mass spectrometry remains a cornerstone for characterizing attributes such as stability, glycosylation, and degradation, but the sheer volume and diversity of resulting data often create workflow bottlenecks. Variability across instruments, software, and sites further complicates data interpretation, heightens risk, and slows decision‑making.

Find out how harmonized, automated MS workflows can resolve these challenges by unifying data processing, improving reproducibility, and scaling with growing analytical demands. Examine the value of flexible, vendor‑neutral platforms that integrate sample preparation, acquisition, and analysis while enabling global collaboration and faster candidate assessment.

Access the full case study to gain a clear view of how modern MS strategies enhance data quality, reduce resource strain, and support confident development decisions.